Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on March 29, 2010. The report details a material definitive agreement entered into on March 24, 2010, by ChromaDex, Inc., a wholly owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The only financial terms disclosed relate to the new agreement:
- Upfront Payment: A cash payment to The University of Mississippi (UM) is required, though the specific amount is not disclosed in this summary.
- Royalties: ChromaDex must pay earned royalties on net sales of licensed products.
- Minimum Annual Royalties: Payments range between $15,000 and $40,000 annually during the term of the agreement.
Material Changes
The primary material change is the execution of a License Agreement with The University of Mississippi. Key terms include:
- Subject Matter: A worldwide, exclusive, non-transferable license to patent rights for Pterostilbene, a compound found in blueberries, grapes, and tree bark.
- Term: The agreement terminates upon the earliest of: (i) expiration of the last patent right, (ii) failure to meet pre-development commercial milestones or default, or (iii) prior written notice by ChromaDex.
- Obligations: ChromaDex is obligated to develop, commercialize, and market licensed products as soon as practicable according to a commercialization development plan.
Guidance, Outlook, and Risks
Management Commentary: The company intends to seek confidential treatment for certain terms of the agreement when filing its Quarterly Report on Form 10-Q for the quarter ended April 3, 2010.
Risks and Contingencies: The agreement is contingent upon ChromaDex meeting specific pre-development commercial milestones. Failure to meet these milestones or a default under the agreement could result in termination of the license.
Investor Verification Checklist
- Verify the exact amount of the upfront cash payment to The University of Mississippi in the upcoming Form 10-Q.
- Review the specific pre-development commercial milestones required to maintain the license.
- Confirm the status of the confidential treatment request for undisclosed agreement terms.
- Assess the impact of the new royalty obligations on future cash flow projections.